D68.021
Von Willebrand disease, type 2B
Clinical Classification Guidelines
Inclusion Terms
- Qualitative defects of von Willebrand factor with high-molecular-weight von Willebrand factor loss
- Qualitative defects of von Willebrand factor with hyper-adhesive forms
- Qualitative defects of von Willebrand factor with increased affinity for platelet glycoprotein lb
Medical Intelligence & Overview
Von Willebrand disease (VWD) is a common bleeding disorder caused by deficiencies or abnormalities in von Willebrand factor (VWF), a protein essential for blood clotting. The type 2B variant, coded as D68.021 in the ICD-10 classification, is characterized by qualitative defects in VWF, leading to increased binding of the factor to platelets. This can cause a reduction in the effective circulating VWF and platelets, resulting in a tendency toward bleeding. Unlike other types of VWD, type 2B is distinguished by its unique effects on the properties of VWF, particularly its enhanced affinity for platelets.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the VWF gene that lead to the production of abnormal VWF molecules. Inheritance as an autosomal dominant trait, meaning only one copy of the altered gene can cause the disorder. The abnormal VWF has heightened affinity for platelet glycoprotein Ib (GPIb), resulting in spontaneous binding and clearance of VWF and platelets. Acquired forms are exceedingly rare but may involve other underlying health conditions or medications affecting VWF. Mutations that result in high-molecular-weight forms of VWF with hyper-adhesive properties.
Key Symptoms: Excessive bleeding following injuries or surgeries. Frequent nosebleeds (epistaxis). Bleeding gums or oral mucosa issues. Heavy or prolonged menstrual periods in women. Bleeding into joints or muscles in severe cases. Easy bruising due to capillary fragility. Spontaneous bleeding episodes without apparent injury. Reduced platelet count during laboratory testing due to increased platelet clearance.
Diagnostic & Treatment
Diagnosis Path: Thorough patient history focusing on bleeding tendencies and family history. Blood tests including an assessment of VWF antigen levels, activity tests (such as ristocetin cofactor activity), and platelet counts. Specialized assays to evaluate the qualitative function of VWF, especially its binding capacity and affinity for platelets. Analysis of high-molecular-weight VWF multimers in plasma samples. Genetic testing may be conducted to identify mutations associated with VWF abnormalities. Differentiation from other types of VWD and bleeding disorders through laboratory profiles and clinical features.
Treatment Protocols: Desmopressin (DDAVP) may be used to temporarily elevate VWF levels and function by stimulating its release from endothelial cells, especially in milder cases. VWF concentrates derived from human plasma are administered for more severe bleeding episodes or prophylaxis before surgeries. Avoidance of medications that impair platelet function, such as aspirin and NSAIDs. Management of bleeding symptoms through supportive care, including local measures and transfusions if necessary. Regular monitoring of blood counts and VWF levels during treatment courses. Emerging therapies and clinical trials exploring targeted treatments for qualitative VWF defects.
Clinical Advice & FAQs
Billing Guidance
Is D68.021 a billable ICD-10 code?
Yes, D68.021 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D68.021?
Clinical documentation must specify the nature of Von Willebrand disease, type 2B and any associated comorbidities for accurate reporting.
Cite this Clinical Reference